Enesi Pharma has entered a partnership with Public Health England (PHE) to develop solid-dose vaccine using the former’s ImplaVax needle-free technology for emerging infections.
Enesi Pharma will focus on the development of solid-dose formulation of different PHE vaccine candidates for delivery through the ImplaVax technology, as part of the agreement.
Based in the UK, Enesi Pharma is a clinical-stage pharmaceutical company, while Public Health England is an executive agency of the Department of Health and Social Care based in the UK.
The collaboration will enable PHE to combine its scientific expertise and resources with Enesi Pharma’s innovative technology to address serious biological threats.
Telix Pharmaceuticals has signed a distribution agreement with Cardinal Health for its 68Ga-HBED-CC-PSMA-11 imaging cold kit (68Ga-PSMA Kit).
The imaging kit, developed by ANMI SA, is used for prostate cancer imaging and will be marketed in the US by Telix’s subsidiary, Telix Pharmaceuticals (US). Cardinal Health will distribute and prepare unit doses of the kit for use in clinical trials, including those sponsored by Telix, under the agreement.
Based in Australia, Telix is a clinical-stage biopharmaceutical company, while Cardinal Health is a healthcare solutions provider.
The deal will enable Cardinal Health to increase the adoption of PSMA-based prostate cancer imaging techniques in the US.
Kite has signed an agreement with HiFiBiO Therapeutics for the discovery and development of neoantigen-reactive T-cell receptors (TCRs) as treatment for different types of cancer.
The alliance intends to use HiFiBiO’s proprietary technology platform to identify shared antigens and neoantigen TCRs, which will be used for the development of cellular therapies.
Kite will pay $10m to HiFiBiO as part of the agreement, while HiFiBiO will also be eligible to receive milestone-based payments.
Based in the US, Kite is a biopharmaceutical company and a subsidiary of Gilead, while HiFiBiO, also based in the US, is a biotherapeutics company.
The collaboration will enable Kite to develop novel anti-neoantigen cell therapies.
GO Therapeutics has signed an agreement with Roche, which gives the latter an exclusive worldwide licence for antibodies developed for cancer-specific targets.
The agreement will also enable Roche to develop and market a new glycol-targeting bispecific antibody.
GO Therapeutics will receive an upfront and near-term milestones payment of $9m as part of the agreement. It will also be eligible to receive $186m in potential milestone payments and royalties.
Based in the US, GO Therapeutics is an immuno-oncology start-up, while Roche is a healthcare company based in Switzerland.
The collaboration will enable Go Therapeutics to develop innovative, tumour-specific antigen therapies.
Taro Pharmaceutical Industries has terminated its agreement with NovaBiotics for the licensing of Novexatin®, a topical treatment for onychomycosis fungal infection.
The drug failed to display superiority over placebo in a Phase IIb study.
Based in the US, Taro is a science-based pharmaceutical company, while NovaBiotics is a UK-based clinical-stage biotechnology company.
Novartis and Boston Pharmaceuticals have signed an agreement for the licensing and development of three novel anti-infective drugs for antibiotic-resistant Gram-negative infections.
Boston Pharmaceuticals will acquire worldwide rights for two drug candidates, LYS228 and IID572, which target carbapenem-resistant enterobacteriaceae, and MAK181 targeting pseudomonas infections, as part of the agreement.
Novartis will receive an upfront payment, royalties and milestone payments following commercialisation of the drug candidates. It will also hold an equity stake in two new companies formed for the development and marketing of the drugs.
Based in Switzerland, Novartis is a pharmaceutical company, while Boston Pharmaceuticals is a US-based novel drug development and commercialisation company.